Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phosphaturia in HIV-Exposed Uninfected Neonates Associated with Maternal Use of Tenofovir Disoproxil Fumarate in Late Pregnancy.

Journal of the Pediatric Infectious Diseases Society·2024
Same author

Approaches to accelerating the study of new antiretrovirals in pregnancy.

Journal of the International AIDS Society·2022
Same author

The impact of COVID-19 on multi-month dispensing (MMD) policies for antiretroviral therapy (ART) and MMD uptake in 21 PEPFAR-supported countries: a multi-country analysis.

Journal of the International AIDS Society·2021
Same author

Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.

PloS one·2021
Same author

The promise of paediatric dolutegravir.

Journal of the International AIDS Society·2021
Same journal

HIV Care Retention and Cost Analysis in Multi-Month ART Dispensing: A Randomized Controlled Trial in China.

Journal of the International AIDS Society·2026
Same journal

Drivers of Vertical HIV Transmission in Sub-Saharan Africa and the Impact and Cost-Effectiveness of Targeted and Universal Lenacapavir Pre-Exposure Prophylaxis.

Journal of the International AIDS Society·2026
Same journal

From Policy to Practice: Brazil's Pathway to Eliminating Vertical Transmission of HIV as a Public Health Milestone.

Journal of the International AIDS Society·2026
Same journal

Progress and Challenges in Elimination of Vertical HIV Transmission.

Journal of the International AIDS Society·2026
Same journal

Optimizing Identification and Care of Pregnant/Breastfeeding Women Living With HIV in Resource-Limited Settings.

Journal of the International AIDS Society·2026
Same journal

From the "Dark Days" to Golden Days: Lessons From the Botswana National Validation Committee's Journey on the Path to Elimination of Vertical Transmission of HIV.

Journal of the International AIDS Society·2026
See all related articles
  1. Home
  3. Getting Back On The Path To Eliminating Hiv In Children.
  1. Home
  3. Getting Back On The Path To Eliminating Hiv In Children.

Related Experiment Video

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

Getting Back on the Path to Eliminating HIV in Children.

George K Siberry1

  • 1Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.

Journal of the International AIDS Society
|June 19, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Global efforts to eliminate pediatric HIV faced setbacks due to funding disruptions. New strategies are needed to overcome barriers and ensure sustained progress in children's HIV control.

Keywords:
eliminationpaediatric HIVvertical transmission

More Related Videos

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Related Experiment Videos

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals
09:27

New Tools to Expand Regulatory T Cells from HIV-1-infected Individuals

Published on: May 30, 2013

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Area of Science:

  • Global Health
  • Infectious Diseases
  • Pediatric Medicine

Background:

  • The COVID-19 pandemic initially tested global resilience in pediatric HIV control.
  • Sudden disruptions in donor support for HIV assistance in 2025 pose existential threats to progress.
  • Despite past successes, recent years show stalled progress in reducing pediatric HIV.
  • Significant gaps remain in eliminating HIV among children globally.

Purpose of the Study:

  • To analyze the impact of funding disruptions on pediatric HIV control.
  • To reframe strategies for ending HIV as a threat to children.
  • To identify key factors and barriers to overcoming remaining gaps in pediatric HIV elimination.
  • To develop a framework for sustained progress in pediatric HIV care, less dependent on donor support.

Main Methods:

  • Review of progress and challenges in global pediatric HIV control.
  • Analysis of the impact of political and financial support disruptions.
  • Identification of strategic pillars for success in pediatric HIV elimination.
  • Framework development for a sustainable, evidence-based approach.

Main Results:

  • Breathtaking reductions in pediatric HIV acquisitions, deaths, and orphanhood since the early 2000s.
  • Progress has stalled in recent years, with persistent gaps in elimination efforts.
  • Disruptions in U.S. government support necessitate strategic reframing and innovation.
  • Key pillars for success include healthcare system integration, national leadership, public-private partnerships, and community engagement.

Conclusions:

  • The current juncture demands a reevaluation of strategies to end pediatric HIV.
  • Overcoming barriers requires robust integration into healthcare systems and strengthened national leadership.
  • Innovation, private sector collaboration, and amplified community voices are crucial.
  • A sustainable, person-centered, and community-informed path is essential to eliminate HIV as a threat to children.